MGNX: MacroGenics, Inc. Stock

by  •  • Comments Off on MGNX: MacroGenics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 952.17
Enterprise Value ($M) 851.21
Book Value ($M) 152.61
Book Value / Share 2.44
Price / Book 6.24
NCAV ($M) 105.53
NCAV / Share 1.69
Price / NCAV 9.02

Profitability (mra)
Return on Invested Capital (ROIC) -0.05
Return on Assets (ROA) -0.03
Return on Equity (ROE) -0.08

Liquidity (mrq)
Quick Ratio 4.46
Current Ratio 4.48

Balance Sheet (mrq) ($M)
Current Assets 251.34
Assets 298.42
Liabilities 145.81
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 58.75
Operating Income -168.24
Net Income -9.06
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -78.20
Cash from Investing -80.08
Cash from Financing 150.36

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Armistice Capital, Llc 7.37 -24.95
02-14 13G/A Ra Capital Management, L.p. 6.50 7.66
02-14 13G T. Rowe Price Investment Management, Inc. 9.10
02-13 13G/A Vanguard Group Inc 6.95 -3.04
02-13 13G/A Bb Biotech Ag 16.00 11.20
01-24 13G/A BlackRock Inc. 9.90 2.50

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSU
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT T
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 71,096 482,783 14.73
2024-05-02 48,567 369,389 13.15
2024-05-01 127,729 430,803 29.65
2024-04-30 120,165 338,442 35.51
2024-04-29 64,146 253,314 25.32

(click for more detail)

Similar Companies
MCRB – Seres Therapeutics, Inc. MDGL – Madrigal Pharmaceuticals, Inc.
ME – 23andMe Holding Co. MGTX – MeiraGTx Holdings plc
MIST – Milestone Pharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io